INSIGHTS ON DRUG DEVELOPMENT
-
A Faster, Human-Based Approach To AAV Optimization
Watch to learn about a human-relevant in vitro liver model and how it can be utilized to measure AAV transduction efficiency, evaluate the toxicity of AAV-based gene therapy vectors, and much more.
-
Streamlining pDNA: Capacity, Complexity, And Cutting-Edge Solutions
Learn how flexible facility design and process innovation are accelerating pDNA manufacturing, as well as key strategies to avoid scale-up pitfalls and meet growing therapeutic demand.
-
Maximizing Laboratory Efficiency With Automated Dual-Thermal Cycling
Accelerate tRNA lead discovery with automated digital PCR. Process 384 samples daily with minimal hands-on time, using dual thermal cyclers to scale from in vitro screening to clinical trials.
-
Navigating Nitrosamine Impurities In Pharmaceutical Drug Development
Understanding formation mechanisms and potency categorization allows developers to mitigate risks early, ensuring regulatory compliance and patient safety without compromising product performance.
-
How To Solve Complex Pediatric Dosing Challenges Using Tailored Solutions8/11/2025
With a partner who understands the science, the regulations, and the real-world demands of dosing children, development can move faster, smarter, and with greater confidence
-
Is Lipinski's Rule Of Five Still Relevant In Drug Development?11/13/2024
Some drugs violate multiple Ro5 elements but remain developable, while some molecules adhere strictly to the Ro5, but their properties are not conducive to development.
-
The Organ-Chip Portfolio10/15/2024
Watch to learn about an organ-chip that has been designed to reduce drug absorption while improving biological modeling to provide researchers with enhanced accuracy in forecasting human drug response.
-
Five Practical Considerations To Move From Concept To Clinic12/17/2025
Learn more about five key factors for advancing targeted in vivo LNP programs, from formulation and targeting strategies to bioanalytical readiness and scalability.
-
Biofluorescent Particle Counters Are Gaining Momentum4/28/2025
The 2025 BioPhorum report highlights challenges and trends in drug filling operations and how they are advancing towards biofluorescent particle counters. Discover an approach that aligns with industry needs.
DRUG DEVELOPMENT SOLUTIONS
-
MabSelect™ VL affinity resin uses a protein L ligand with strong affinity for the variable region of a human antibody’s kappa light chain. The resin offers high productivity and robust processes for affinity capture of bispecific antibodies and antibody fragments containing the kappa light chain and offers a good capture alternative for antibody variants that does not bind to protein A.
-
Learn how high‑potency infrastructure, strong impurity control, and scalable payload‑linker capabilities help teams manage risk, maintain purity, and advance toward clinical‑stage ADC development.
-
Used Elizabeth Hata R&D tablet press, model EP200, B/D tooled with 10 station turret, 5 stations each B and D, 16 mm B, 22 mm D max tablet diameter, 17 mm B, 18 mm D max depth of fill, rated up to 6000 tablets/hour, with feed hoppers and feed frames, Machine #81, built 2011.
-
GO BEYOND with the SCIEX 7500 system, high performance triple quadrupole LC-MS/MS mass spectrometer
Enter a new era of sensitivity and LC-MS/MS innovation with the SCIEX 7500 system. GO BEYOND current limits of sensitivity, productivity targets, ruggedness and robustness challenges. Pioneer new discoveries with this innovation.
-
Explore a system that has revolutionized analytical science and delivers faster throughput, sharper resolution, and reliable data to accelerate discovery and elevate your lab’s performance.